Education
About Us
Working with TipRanks
Follow Us
IO Biotech (IOBT)
NASDAQ:IOBT
IOBT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.66 - $1.80
Previous CloseN/A
Volume57.25K
Average Volume (3M)178.48K
Market Cap
$77.08M
Enterprise Value-$8.99M
Total Cash (Recent Filing)-$7.85M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Mar 27, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.37
Shares Outstanding65,880,910
10 Day Avg. Volume275,037
30 Day Avg. Volume178,482
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.89
Enterprise Value/Ebitda0.10
Forecast
1Y Price Target
$9.00Price Target Upside650.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
IO Biotech News
PremiumCompany Announcements
IO Biotech Advances Phase 3 Trial and Secures Financing
PremiumCompany Announcements
IO Biotech Secures €57.5 Million EIB Loan Facility---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe delay in the Phase 3 trial could indicate that patients are living longer than expected, which could be a positive signal of a longer median PFS with Cylembio.
Efficacy DataThe Phase 1 study showed a median PFS of 22.5 months with IO102-IO103 + nivolumab, compared to the expected 11-12 months with checkpoint inhibitors alone.
Regulatory MilestonesThe company's guidance for a potential BLA submission in 2025 and full approval and launch in 2H26 remains unchanged.
Bears Say
Regulatory UncertaintyThe interim results from the Phase 3 study did not meet statistical significance, and there is uncertainty regarding the numerical benefit in the treatment arm as the ORR numbers were not disclosed.
Safety ConcernsThe safety profile showed Grade 3-4 treatment-related adverse events in 24% of patients, which is slightly higher than some comparable studies.
Treatment DiscontinuationThe treatment-related discontinuations were higher at 16% compared to a lower rate in other studies.
---
Ownership Overview
28.12% Insiders
0.31% Mutual Funds
21.16% Other Institutional Investors
50.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IOBT FAQ
What was IO Biotech’s price range in the past 12 months?
IO Biotech lowest stock price was $0.66 and its highest was $1.80 in the past 12 months.
What is IO Biotech’s market cap?
IO Biotech’s market cap is $77.08M.
When is IO Biotech’s upcoming earnings report date?
IO Biotech’s upcoming earnings report date is Mar 27, 2025 which is yesterday.
How were IO Biotech’s earnings last quarter?
Currently, no data Available
Is IO Biotech overvalued?
According to Wall Street analysts IO Biotech’s price is currently Undervalued.
Does IO Biotech pay dividends?
IO Biotech does not currently pay dividends.
What is IO Biotech’s EPS estimate?
IO Biotech’s EPS estimate is -0.38.
How many shares outstanding does IO Biotech have?
IO Biotech has 65,880,910 shares outstanding.
What happened to IO Biotech’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of IO Biotech?
Among the largest hedge funds holding IO Biotech’s share is RA Capital Management. It holds IO Biotech’s shares valued at 0.
---
IO Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (650.00% Upside)
$9.00 (650.00% Upside)
Blogger Sentiment
Bullish
IOBT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $26.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.78%
12-Months-Change
Fundamentals
Return on Equity
-78.50%
Trailing 12-Months
Asset Growth
-47.87%
Trailing 12-Months
Company Description
IO Biotech
IO Biotech (IOBT) is a biotechnology company focused on the development of innovative cancer therapies. The company is engaged in the research and development of immune-modulating treatments that aim to harness the body's own immune system to combat cancer. IO Biotech's core product candidates are based on its proprietary T-win technology platform, which seeks to activate T cells to target cancer cells specifically.
---
IOBT Stock 12 Month Forecast
Average Price Target
$9.00
▲(650.00% Upside)
Technical Analysis
Agenus
―
Fate Therapeutics
―
Intra-Cellular Therapies
―
Blueprint Medicines
―
Adaptimmune Therapeutics
―
Best Analysts Covering IOBT
1 Year
1 Year Success Rate
4/15 ratings generated profit
1 Year Average Return
-15.30%
reiterated a buy rating 24 days ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 26.67% of your transactions generating a profit, with an average return of -15.30% per trade.
---